Why AstraZeneca’s Truqap win could force a new testing era in prostate cancer
Find out how AstraZeneca’s Truqap approval could reshape PTEN-deficient prostate cancer treatment and biomarker testing.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Can Veracyte’s Decipher Prostate test change who gets chemotherapy in metastatic prostate cancer?
Can Veracyte’s Decipher Prostate test change chemotherapy decisions in metastatic prostate cancer? Find out what ENZAMET data means today.
Pharma & Biotech
What Syncromune Inc.’s SYNC-T data reveals about the future of combination immunotherapy
Discover how Syncromune Inc.’s SYNC-T data could reshape combination immunotherapy. Find out what this means for cancer treatment innovation.
Pharma & Biotech
Can TCR bispecifics unlock prostate cancer immunotherapy? Why Pfizer is backing Flagship and Repertoire
Flagship Pioneering has launched a new research program with Pfizer through its portfolio company Repertoire Immune Medicines, focused on the development of T cell receptor (TCR) bispecifics for metastatic prostate cancer. This marks the eighth initiative under the broader Flagship–Pfizer strategic alliance. The program will harness Repertoire’s DECODE platform to map immune synapse interactions and